CHRONIC SPONTANEOUS URTICARIA

This study is observing how well a new oral drug called remibrutinib works for adults with chronic spontaneous urticaria (CSU), a condition causing long-lasting hives. It will follow about 500 people in the US for two years to see how effectively the drug controls their symptoms …

This study is testing an investigational oral drug called BLU-808 for people with chronic hives that are not well-controlled by standard allergy medicines. The main goals are to see if the drug is safe and if it can reduce hive symptoms and flare-ups. The trial will enroll about …

This study is for adults with chronic spontaneous urticaria (CSU), also known as chronic hives, who have already completed one of two earlier Phase 3 trials for the drug barzolvolimab. The main goal is to collect long-term data on how well the drug continues to control hives and …

This program provides access to the investigational drug remibrutinib for adults with severe chronic hives (CSU) that hasn't responded to standard treatments. It's for patients who cannot join a regular clinical trial. The goal is to help control this difficult skin condition whe…

This study aims to understand how well the drug dupilumab works for people with chronic spontaneous urticaria (CSU), also known as chronic hives, in everyday life. It will follow 400 patients in the U.S. for two years, collecting information from their medical records and their o…

This study aims to see how well a drug called remibrutinib works for people with chronic hives in real-world settings, outside of a controlled clinical trial. It will enroll 350 adults in the US who are starting this medication. Researchers will track how well the drug controls h…

This study is testing a new version of a drug called omalizumab (CMAB007) for people with chronic hives that don't respond to standard allergy pills. It will compare this new version directly to the already-approved drug Xolair to see if they work the same. About 392 participants…

This study is testing an oral medication called ritlecitinib to see if it can safely reduce itchy hives and swelling in adults with chronic spontaneous urticaria (CSU) that isn't controlled by standard allergy medicines. About 200 participants will be randomly assigned to take ei…

This study is testing a new drug called EVO756 to see if it can reduce the severity of chronic hives in adults. It will compare several doses of the drug against a placebo in 160 people whose hives are not well-controlled by standard allergy pills. The main goal is to see how muc…

This study is testing if patients with chronic hives that are already well-controlled with a monthly injection can safely switch to receiving that injection every six weeks. The goal is to see if the less frequent schedule works just as well at keeping symptoms under control. Abo…

This study aims to see how well a new drug called remibrutinib works for controlling chronic spontaneous urticaria (CSU), or long-lasting hives, in everyday medical practice. It will follow about 3,280 adults whose doctors have already decided to either increase their current all…

This is a very early, first-in-human study to check if a new oral drug called HRS-3095 is safe and how it behaves in the body. It involves healthy volunteers, not people with the condition it's intended for (chronic hives). The main goal is to understand the drug's safety profile…

This study is creating a large registry of patients with conditions like eczema, psoriasis, and alopecia areata to track how treatments work in real-world settings. Researchers will follow 15,000 adults and children over time to understand treatment safety, effectiveness, and how…